The Denial Economy in 2026: What the Latest Surveys and Policy Moves Show

UnitedHealthcare began eliminating 30% of its prior authorization requirements Oct. 1 across its commercial, Medicare Advantage, Community, Individual Exchange and Oxford plans, a cut that covers roughly 1,700 codes, according to Healthcare Dive. The change lands as more providers report claims ending in final denial. One in five respondents to the latest HFMA/Guidehouse survey reported a final denial rate above 5%, up from 12% a year earlier.

Payer and federal policy are moving in two directions at once. CMS finalized a 2.3% inpatient rate update for fiscal 2027, and starting Oct. 15 it will add a new prior authorization requirement for newly enrolled DME suppliers. Read alongside a separate Black Book Research survey of revenue cycle leaders, the developments show payment friction shifting across the claim lifecycle, with outpatient and multi-site groups absorbing a growing share of the cost of disputing payment for care already delivered.

UnitedHealthcare trims prior authorization on high-approval services

The cut includes more than 800 codes for commercial plans, about 940 for ACA plans and roughly 120 for Medicare Advantage and dual special needs plans, Healthcare Dive reported. The lists span orthopedic and musculoskeletal procedures, cardiology, oncology, lab and genetic testing, therapy services and durable medical equipment. The insurer also published a list of providers newly qualifying for its national gold card program, which lets practitioners with consistently approved requests perform most procedures without seeking approval, according to the outlet.

The insurer focused on services with proven clinical efficacy and consistently high approval rates, a UnitedHealthcare spokesperson told the outlet. When it announced the commitment in May, UnitedHealth said just 2% of services were subject to prior authorization and 92% of submissions were approved, according to Fierce Healthcare. The same report cited a KFF analysis that found UnitedHealthcare had the highest standard prior authorization denial rate in Medicare Advantage in 2025, at 17%, Fierce noted. The broader industry is moving in the same direction. An April update from AHIP and the Blue Cross Blue Shield Association suggested plans had reduced prior authorizations by 11% overall under an industry pledge unveiled the prior summer, Fierce reported.

For procedural groups, the published code lists offer real relief. Because the requirements going away were largely the ones already being approved, the change may do less for denial rates than the 30% headline suggests. The open question for revenue cycle teams is whether denial rates on those codes actually fall over the next few quarters, or whether scrutiny resurfaces later as medical necessity denials and downcoding.

Survey finds medical groups report the highest final denial rates

HFMA and Guidehouse surveyed 191 provider executives in late 2025, nearly half of them CFOs, and published the results April 1. Eighty-eight percent said disagreements over claims keep their organizations from getting paid on time and in full. Respondents reported more denials (81%), longer prior authorization delays (74%) and more unclear denial reasons or underpayments (73%).

The split by organization type stands out. Thirty-nine percent of medical group executives and 25% of hospital executives reported final denial rates above 5%, according to the report, while more than half of health system executives reported rates of 2% or lower. Medical groups made up a small share of respondents, so the split is directional. Still, it suggests the organizations with the least scale to absorb rework are carrying the highest final denial rates.

"Our findings reinforce the need for health system leaders to invest in payer strategy and contract management to find common ground with health plans and reduce friction that slows reimbursement," Andrew Hancock, partner and payer/provider financial solutions leader at Guidehouse, said in the release. Technology adoption remains early. Nearly 60% of executives said they had not yet implemented any AI or automation in revenue cycle operations, and just 2% said these tools were fully or mostly integrated.

Revenue cycle leaders tell Black Book prevention is the priority

A separate Black Book Research report released June 4, drawing on six surveys of 882 provider-side executives and end users fielded between December 2025 and June 2026, reached a similar read on payer pressure. "Revenue cycle management has reached its boardroom moment," founder Doug Brown said.

Seventy-eight percent of respondents ranked payer friction among their top three RCM technology stressors, according to the report. Seventy-four percent prioritized denial prevention over post-denial recovery, and 71% ranked prior authorization as a top-three operational bottleneck for revenue realization. Seventy-three percent reported automation in at least one RCM workflow, though 58% said that automation remains fragmented across tools, departments or suppliers. Sixty-six percent said their current RCM analytics are insufficient for CFO-level revenue predictability decisions.

The report also placed more of the problem at the front end. Seventy-six percent of respondents linked front-end data quality directly to denials or cash timing, and 72% said patient responsibility has become harder to collect than in the prior operating cycle. On AI, 69% said human-in-the-loop controls are required before AI can take claim, appeal, coding or patient-contact actions, and 63% said auditability and explainability are mandatory for RCM workflows.

The two surveys measure automation differently and arrive at different adoption figures, a gap that likely reflects sample and definitions as much as the market. Neither measures whether prevention spending has brought denials down, and a stated priority describes intent. For finance leaders, that leaves a harder question: how much of their own denial volume was preventable at scheduling or registration, and whether that number ever reaches the board.

Medicare's 2.3% inpatient update offers a modest cushion

CMS released the FY 2027 IPPS final rule July 31, 2026. The rule was published in the Federal Register Aug. 4 and took effect Oct. 1. It finalizes a 2.3% increase in inpatient payment rates (a 3.2% market basket update minus a 0.9 percentage point productivity adjustment) for hospitals that meet quality reporting and EHR requirements. CMS expects the changes to raise hospital payments by about $2.1 billion, plus roughly $779 million in new technology add-on payments, according to the agency's fact sheet.

For hospital-affiliated groups, 2.3% is a modest offset against rising denials on commercial and Medicare Advantage claims, where payer rules run independently of CMS rate-setting. The rule also matters to orthopedic and ASC operators. It finalizes CJR-X, a mandatory nationwide bundled payment model for hip, knee and ankle replacements in inpatient and hospital outpatient settings, beginning Jan. 1, 2028. For joint replacement programs, that raises the question of how well they know what a case costs to collect, alongside what it costs to perform.

CMS adds prior authorization for new DME suppliers

While UnitedHealthcare trims prior authorization, CMS is adding it where it sees fraud risk. A six-month nationwide moratorium on Medicare enrollment for seven types of DMEPOS medical supply companies took effect Feb. 27, 2026, and expired Aug. 27, according to CHAP's compliance monitor. Starting Oct. 15, CMS will require probationary prior authorization for listed DMEPOS items billed by newly enrolled suppliers and suppliers with certain ownership changes, for one year. Groups that route patients to DME suppliers for post-surgical equipment should expect newer suppliers to face an extra approval step.

The next few months will show which way the friction moves. UnitedHealthcare's code cuts are now live, the DME requirement starts Oct. 15, and CJR-X is a little more than two years out. If final denial rates keep climbing on services that no longer need approval, the 2027 contracting cycle is likely to be fought over post-service review, underpayments and denial rationales. Every hour payers and providers spend contesting claims for care already delivered is administrative cost with no clinical value, and the groups that can measure their own payer friction will be the ones positioned to price it into those contracts.